BioSight
Companies
Edesa Biotech, Inc. logo

EDSA

NASDAQMARKHAM
Edesa Biotech, Inc.

Edesa Biotech is a biopharmaceutical company developing treatments for inflammatory and immune-related diseases, with a focus on medical dermatology and respiratory conditions. Its pipeline includes EB06, a monoclonal antibody in Phase 2 development for vitiligo; EB01, a Phase 3-ready cream for allergic contact dermatitis that is being partnered out; and EB05 (paridiprubart), a host-directed therapeutic that recently met primary and secondary endpoints in a Phase 3 study for acute respiratory distress syndrome. All candidates are built on mechanisms that have shown proof-of-concept in human studies, targeting areas with significant unmet medical needs.

Price history not yet available for EDSA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar